AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29980851 — intervention group
Group type: COMPARATOR
Intervention: Control (75 g oral glucose tolerance test)
Number of subjects: 8
Study 26916611 — intervention group
Group type: EXPERIMENTAL
Intervention: EXCAP (home-based walking and resistance intervention)
Number of subjects: 19
Study 26916611 — intervention group
Group type: EXPERIMENTAL
Intervention: EXCAP
Number of subjects: 19
Study 26916611 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii-Fit (technology-mediated walking and resistance intervention)
Number of subjects: 19
Study 26916611 — intervention group
Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 19
Study 25255414 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback to residents alone
Number of subjects: 0
Study 25255414 — intervention group
Group type: COMPARATOR
Intervention: Real-time feedback to residents plus attending physicians
Number of subjects: 0
Study 22153087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound scalpel
Number of subjects: 60
Study 22153087 — intervention group
Group type: COMPARATOR
Intervention: Standard scalpel blades, scissors, ligations, and electrocautery
Number of subjects: 60
Study 20443797 — intervention group
Group type: EXPERIMENTAL
Intervention: Conical neck design implant (C)
Number of subjects: 12
Study 20443797 — intervention group
Group type: COMPARATOR
Intervention: Straight shape implant (S)
Number of subjects: 12
Study 18509655 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 72
Study 15947874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of fruit (highest vs lowest quintile)
Number of subjects: 36976
Study 15947874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of vegetables (highest vs lowest quintile)
Number of subjects: 36976
Study 15947874 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fiber intake (highest vs lowest quintile)
Number of subjects: 36976
Study 15947874 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume fiber intake (highest vs lowest quintile)
Number of subjects: 36976
Study 12352800 — intervention group
Group type: EXPERIMENTAL
Intervention: CRM(197) pneumococcal conjugate vaccine (PCV)
Number of subjects: 0
Study 12352800 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal type C CRM(197) conjugate vaccine
Number of subjects: 0
Study 10023873 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 112
Study 10023873 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 112
Study 7754005 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE) with gelatin sponge (GS) containing anticancer agents (protocol 1)
Number of subjects: 322
Study 7754005 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE) with GS and iodized oil mixed with anticancer agents (protocol 2)
Number of subjects: 322
Study 7754005 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE) with iodized oil with anticancer agents (protocol 3)
Number of subjects: 322
Study 7754005 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial embolization (TAE) with GS
Number of subjects: 322
Study 2186321 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOEP (cyclophosphamide 750 mg/m2 i.v. day 1, doxorubicin 50 mg/m2 i.v. day 1, vincristine 2 mg i.v. day 1, etoposide 100 mg/m2 i.v. days 3-5, prednisolone 100 mg p.o. days 1-5)
Number of subjects: 105
Study 2186321 — intervention group
Group type: COMPARATOR
Intervention: hCHOP alternating with IVEP (cyclophosphamide 1,200 mg/m2 i.v. day 1, doxorubicin 40 mg/m2 i.v. days 1 + 2, vincristine 2 mg i.v. day 1, prednisolone 100 mg p.o. days 1-5)
Number of subjects: 105
Study 6271848 — intervention group
Group type: EXPERIMENTAL
Intervention: delta‐9‐tetrahydrocannabinol
Number of subjects: 27
Study 6271848 — intervention group
Group type: EXPERIMENTAL
Intervention: cannabidiol
Number of subjects: 27
Study 6271848 — intervention group
Group type: EXPERIMENTAL
Intervention: cannabinol
Number of subjects: 27
Study 6271848 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 6271848 — intervention group
Group type: COMPARATOR
Intervention: comparison group (nondrug users)
Number of subjects: 27
Study 31916847 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 196
Study 31916847 — intervention group
Group type: COMPARATOR
Intervention: Depression
Number of subjects: 196
Study 31916847 — intervention group
Group type: COMPARATOR
Intervention: Anxiety
Number of subjects: 196
Study 31153358 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp nerve block (SNB) with 15 mL of 0.75% ropivacaine
Number of subjects: 57
Study 31153358 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic infiltration (LA) with 15 mL of 0.75% ropivacaine
Number of subjects: 57
Study 31153358 — intervention group
Group type: COMPARATOR
Intervention: Routine intravenous analgesia (Control group)
Number of subjects: 57
Study 28636855 — intervention group
Group type: EXPERIMENTAL
Intervention: RIV4 (45 μg of recombinant hemagglutinin [HA] per strain, 180 μg of protein per dose)
Number of subjects: 9003
Study 28636855 — intervention group
Group type: COMPARATOR
Intervention: IIV4 (15 μg of HA per strain, 60 μg of protein per dose)
Number of subjects: 9003
Study 28636855 — intervention group
Group type: EXPERIMENTAL
Intervention: RIV4
Number of subjects: 9003
Study 25583168 — intervention group
Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF)
Number of subjects: 200
Study 25583168 — intervention group
Group type: COMPARATOR
Intervention: efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF)
Number of subjects: 200
Study 24163991 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic positive airway pressure (APAP) titration
Number of subjects: 50
Study 24163991 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography manual titration
Number of subjects: 50
Study 21324544 — intervention group
Group type: EXPERIMENTAL
Intervention: DLCST participants
Number of subjects: 3999
Study 21324544 — intervention group
Group type: COMPARATOR
Intervention: Comparable population sample
Number of subjects: 3999
Study 19752576 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17683212 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 0
Study 17683212 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 0
Study 15526811 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 69
Study 15526811 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 69
Study 11533270 — intervention group
Group type: EXPERIMENTAL
Intervention: (n‐3) PUFA
Number of subjects: 35
Study 11533270 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 35
Study 11533270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11533270 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 35
Study 9762784 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (10(-3) M)
Number of subjects: 0
Study 9762784 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (10(-4) M)
Number of subjects: 0
Study 9762784 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 0
Study 8156653 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg (0.2-0.3 mg/kg)
Number of subjects: 0
Study 8156653 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 12.5 mg (0.1-0.2 mg/kg)
Number of subjects: 0
Study 8156653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3131791 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.695 g/kg)
Number of subjects: 0
Study 3131791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31690107 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of directly observed once-weekly rifapentine plus isoniazid
Number of subjects: 7452
Study 31690107 — intervention group
Group type: COMPARATOR
Intervention: 9 months of self-administered daily isoniazid
Number of subjects: 7452
Study 29769112 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 523
Study 28098052 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counselling on breast-feeding and complementary feeding during the 1st year of life (n=200)
Number of subjects: 500
Study 28098052 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=300)
Number of subjects: 500
Study 26433466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-I)
Number of subjects: 64
Study 26433466 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Training (RT)
Number of subjects: 64
Study 23231878 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behavioural therapy for psychosis (CaCBTp)
Number of subjects: 35
Study 23231878 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 35
Study 21209123 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA160/80 (160 mg at week 0, 80 mg at week 2, 40 mg at weeks 4 and 6)
Number of subjects: 390
Study 21209123 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA80/40 (80 mg at week 0, 40 mg at weeks 2, 4 and 6)
Number of subjects: 390
Study 21209123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 18282804 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared-care model involving paediatric oncologists and family doctors
Number of subjects: 133
Study 17033926 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy plus tamoxifen for 1 year
Number of subjects: 311
Study 17033926 — intervention group
Group type: COMPARATOR
Intervention: CMF chemotherapy for 1 year
Number of subjects: 311
Study 17033926 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF plus tamoxifen with BCG during the second year
Number of subjects: 311
Study 17033926 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients diagnosed with ER+ tumors
Number of subjects: 311
Study 15475273 — intervention group
Group type: EXPERIMENTAL
Intervention: Education for asthma management (individual or collective education)
Number of subjects: 66
Study 11524100 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound dressings
Number of subjects: 45
Study 9573748 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogens alone administered transdermically (17 beta‐estradiol, 50 micrograms/day)
Number of subjects: 84
Study 9573748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (0.625 mg/day)
Number of subjects: 84
Study 9573748 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermic estrogens plus oral progestagen (17 beta‐estradiol 50 micrograms/day, acetate medroxyprogestogen 10 mg/day for 12 days per month)
Number of subjects: 84
Study 9573748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (0.625 mg/day) plus oral progestagen (10 mg/day for 12 days per month)
Number of subjects: 84
Study 9573748 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 84
Study 8179948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices (n=13)
Number of subjects: 3850
Study 8179948 — intervention group
Group type: COMPARATOR
Intervention: Control practices (n=13)
Number of subjects: 3850
Study 3282825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 25
Study 3282825 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 25
Study 30189674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaner-burning biomass-fueled cookstoves
Number of subjects: 1928
Study 30189674 — intervention group
Group type: COMPARATOR
Intervention: Location (Chikhwawa versus Chilumba)
Number of subjects: 1928
Study 30189674 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between mean CO and COHgB
Number of subjects: 1928
Study 26581073 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 75
Study 26581073 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 75
Study 26581073 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 23879294 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPO (hypoxic training, FiO(2) = 15%)
Number of subjects: 20
Study 23879294 — intervention group
Group type: COMPARATOR
Intervention: NOR (normoxic training, FiO(2) = 20·9%)
Number of subjects: 20
Study 23879294 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 22731789 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Outcome (GO) cases of EFT
Number of subjects: 6
Study 22731789 — intervention group
Group type: COMPARATOR
Intervention: Poor Outcome (PO) cases of EFT
Number of subjects: 6
Study 20470802 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF treatment plus DMARDs
Number of subjects: 63
Study 20470802 — intervention group
Group type: COMPARATOR
Intervention: DMARDs only (Control)
Number of subjects: 63
Study 20470802 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Anti-TNF and Control)
Number of subjects: 63
Study 18768401 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postnatal weight gain (0 to 5 months)
Number of subjects: 679
Study 18768401 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain between 1 year and 9 months to 5 years
Number of subjects: 679
Study 15821690 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional appliances (Fränkel II or Herbst); average treatment duration to final cephalograms: 35.8 months
Number of subjects: 60
Study 15821690 — intervention group
Group type: COMPARATOR
Intervention: Bilateral sagittal split ramus osteotomy; average treatment duration to final cephalograms: 34.9 months
Number of subjects: 60
Study 12388961 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone gel 5 mg intracervically, with repeated dosing one time 6 hours later
Number of subjects: 32
Study 9973008 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular outflow tract (RVOT) pacing
Number of subjects: 16
Study 9973008 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 16
Study 7588670 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 100 mg suppositories
Number of subjects: 22
Study 7588670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2105670 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard in-line filters
Number of subjects: 88
Study 2105670 — intervention group
Group type: COMPARATOR
Intervention: Sham in-line filters
Number of subjects: 88
Study 2105670 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol-based peripheral hyperalimentation solution (after eliminating in-line filters)
Number of subjects: 88
Study 477550 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline ethylenediamine
Number of subjects: 0
Study 477550 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of theophylline, diprophylline, and proxyphylline
Number of subjects: 0
Study 31870451 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy with protein-rich nutritional supplement plus anabolic steroid
Number of subjects: 48
Study 31870451 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy with protein-rich nutritional supplement plus placebo
Number of subjects: 48
Study 28291238 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram (ESC)
Number of subjects: 256
Study 28291238 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg amitriptyline (AMI)
Number of subjects: 256
Study 28291238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 25884358 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate and high calorie oral nutritional supplement
Number of subjects: 53
Study 25884358 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication and low calorie oral nutritional supplementation
Number of subjects: 53
Study 23621805 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual music therapy for 6 weeks
Number of subjects: 42
Study 23621805 — intervention group
Group type: COMPARATOR
Intervention: Standard care for 6 weeks
Number of subjects: 42
Study 21412143 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrahepatic IVC clamping
Number of subjects: 152
Study 21412143 — intervention group
Group type: COMPARATOR
Intervention: Control group (anesthesiological interventions including fluid restriction)
Number of subjects: 152
Study 19132197 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day for 10 days
Number of subjects: 36
Study 19132197 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg on day 11
Number of subjects: 36
Study 19132197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17324742 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (3 mg/kg intravenously)
Number of subjects: 12
Study 17324742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15002070 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (15,000 IU/kg)
Number of subjects: 39
Study 15002070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (10 mg/kg)
Number of subjects: 39
Study 15002070 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 39
Study 15002070 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin group (n = 12)
Number of subjects: 39
Study 15002070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline group (n = 11)
Number of subjects: 39
Study 11277274 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg single-dose infusion)
Number of subjects: 47
Study 11277274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 9688484 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 52
Study 9688484 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 52
Study 9688484 — intervention group
Group type: COMPARATOR
Intervention: Doppler ultrasound studies
Number of subjects: 52
Study 8083102 — intervention group
Group type: EXPERIMENTAL
Intervention: lonidamine + radiation therapy
Number of subjects: 310
Study 8083102 — intervention group
Group type: COMPARATOR
Intervention: placebo + radiation therapy
Number of subjects: 310
Study 2536765 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg fluoxetine
Number of subjects: 0
Study 2536765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 338109 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg PGE2 in 2% gel
Number of subjects: 168
Study 338109 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg PGE2 in 4% gel
Number of subjects: 168
Study 30801900 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green-guided nonpalpable breast cancer lesion localization (INBCL)
Number of subjects: 62
Study 30801900 — intervention group
Group type: COMPARATOR
Intervention: Wire localization (WL)
Number of subjects: 62
Study 28659419 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study 28659419 — intervention group
Group type: EXPERIMENTAL
Intervention: DNR/comfort care decisions
Number of subjects: 0
Study 25875943 — intervention group
Group type: EXPERIMENTAL
Intervention: Community weight gain prevention program
Number of subjects: 28
Study 24887490 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 20 mg/day lutein and 2 mg/day zeaxanthin
Number of subjects: 52
Study 24887490 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: 10 mg/day meso-zeaxanthin, 10 mg/day lutein, and 2 mg/day zeaxanthin
Number of subjects: 52
Study 24887490 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: 17 mg/day meso-zeaxanthin, 3 mg/day lutein, and 2 mg/day zeaxanthin
Number of subjects: 52
Study 22818396 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy oriented group intervention (4-week program)
Number of subjects: 156
Study 22818396 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 156
Study 19130163 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia and/or analgesia
Number of subjects: 1538
Study 19130163 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia and/or systemic analgesia
Number of subjects: 1538
Study 17728216 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Number of subjects: 200
Study 17728216 — intervention group
Group type: COMPARATOR
Intervention: Control (nondirective empathic listening)
Number of subjects: 200
Study 15588321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve prolapse (MVP) with celiac artery stenosis (CAS)
Number of subjects: 3780
Study 15588321 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve prolapse (MVP) without celiac artery stenosis (CAS)
Number of subjects: 3780
Study 15588321 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Systolic Velocity (PSV) in MVP patients
Number of subjects: 3780
Study 11783835 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for chronic low back pain
Number of subjects: 0
Study 11783835 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for fibromyalgia
Number of subjects: 0
Study 11783835 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for chronic neck pain
Number of subjects: 0
Study 11783835 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for upper extremity pain (chronic lateral epicondylitis and specific soft tissue shoulder disorders)
Number of subjects: 0
Study 11783835 — intervention group
Group type: COMPARATOR
Intervention: Exercise for chronic neck pain and chronic soft tissue shoulder disorders and chronic lateral epicondylitis
Number of subjects: 0
Study 9338554 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluticasone propionate
Number of subjects: 17
Study 9338554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9338554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (after antigen challenge)
Number of subjects: 17
Study 9338554 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glucocorticoid therapy
Number of subjects: 17